The result is BIOMEnd, a product that addresses common challenges often found in butyrate supplements such as unpleasant taste and solubility issues.
So far, Sojka said BIOMEnd has been well-received:
“We’ve successfully done plenty of ready-to-mix powders already in terms of different various flavors. And actually, I’ve been working with a couple of companies on developing a RTD stable version with one company already having success with it. So, you know, we’ll have an RTD version available here very soon.”
Sojka added that BIOMEnd has broader potential in metabolic health, cognitive function and mood enhancement, positioning it to become the next breakthrough supplement in the supplement industry.
“I’m a huge believer in butyrate and all the various things it does way beyond the gut,” said Sojka. “Over the next decade, I think butyrate is going to become a household name, based off of the research that I’ve done so far. I think it genuinely will be a household name like creatine or, you know, a typical vitamin, fish oil, things that everyone knows that they should be taking. I think butyrate will be a nutrient that will be on that list.”
Looking ahead, NutraShure plans to conduct further research to tie serum butyrate levels to gut health and explore its effects on GLP-1. In addition to research, the company is slated to launch new products on its annual “Innovation Day” on May 1, with a pipeline of seven to eight new ingredients in development.
To hear more about the research on BIOMEnd, including its pharmacokinetic advantages and what to expect on May 1, listen to the NutraCast.
If you enjoy listening to the NutraCast, feel free to leave a review. You can subscribe on Apple, iHeart, Spotify or wherever you get your podcasts.
